Agoracom Blog Home

Posts Tagged ‘THC’

Tetra Bio-Pharma $TBP.ca Announces $8 million Bought Deal Offering $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 9:47 AM on Thursday, February 8th, 2018

Logo tetrabiopharma rgb web

  • Entered into a bought deal financing agreement to sell 8,000,000 units of the Company at a price of $1.00 per Unit for gross proceeds of approximately $8.0 million
  • Each Unit will consist of one common share  in the Company and one warrant
  • Each Warrant will entitle the holder thereof to acquire one Common Share at a price of $1.30, for a period of 36 months from the Closing Date

NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATES

ORLEANS, Ontario, Feb. 08, 2018 — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP) (OTCQB:TBPMF) a global leader in cannabinoid-based drug development and discovery, announced today that it has entered into a bought deal financing agreement to sell 8,000,000 units of the Company (the “Units”) at a price of $1.00 per Unit for gross proceeds of approximately $8.0 million (the “Offering”).

Each Unit will consist of one common share (a “Common Share”) in the Company and one warrant (a “Warrant” and collectively the “Warrants”). Each Warrant will entitle the holder thereof to acquire one Common Share at a price of $1.30, for a period of 36 months from the Closing Date.

The Offering will be conducted by a syndicate of underwriters led by Echelon Wealth Partners Inc. (collectively, the “Underwriters”). Tetra Bio-Pharma has granted the Underwriters an over-allotment option to purchase up to an additional 1,200,000 Units at the offering price, exercisable for a period of 30 days after closing. If the over-allotment option is exercised in full, the gross proceeds from the Offering will be approximately $9.2 million.

“We are extremely pleased to partner with Echelon Wealth Partners in securing this financing agreement. As we are about to initiate our Health Canada’s recently approved phase 3 registration trial for our lead drug candidate, PPP001, in late stage cancer patients, the proceeds from this Offering will enable Tetra to continue, and even accelerate some of the key development projects in our pipeline.  This is another milestone in working towards becoming the first biopharmaceutical company in the world to get a smokable dried cannabis product approved as a prescription drug by Health Canada, the FDA and other regulatory agencies around the world,” states Bernard Fortier, CEO of Tetra Bio-Pharma.

The Company intends to use the net proceeds of the Offering to advance the Company’s Phase 3 trial for PPP001 and other clinical trials, to effect the repayment of indebtedness and for general corporate and working capital purposes.

The Offering will be completed by way of a short form prospectus to be filed in all provinces of Canada and on a private placement basis in the United States pursuant to exemptions from the registration requirements of the United States Securities Act of 1933, as amended (the “U.S. Securities Act”).

The Offering is expected to close on or about February 28, 2018 and is subject to customary closing conditions including, but not limited to, the approval of securities regulatory authorities and the TSX Venture Exchange’s approval.

The securities described herein have not been, and will not be, registered under the U.S. Securities Act or any state securities laws, and accordingly, may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities requirements or pursuant to exemptions therefrom. This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Tetra Bio-Pharma

Tetra Bio-Pharma (TSX-V:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a license for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.

Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
anne-sophie.courtois@tetrabiopharma.com
(514) 360-8040 Ext. 210

For media information, please contact:

Daniel Granger
Daniel.granger@acjcommunication.com
ACJ Communication
O: 1 514 840 7990 / M: 1 514 232 1556

INTERVIEW – Namaste $N.ca $NXTTF Global Bevarage Supply Agreement With Phivida $VIDA.ca Sets It On The Path Towards Becoming “Namazon”

Posted by AGORACOM-JC at 8:08 PM on Thursday, January 11th, 2018

Today’s press release from Namaste is one of the most important in recent months – but you wouldn’t know it from the press release headline announcing a “supply agreement”.
This is no ordinary supply agreement … this is a GLOBAL supply agreement for CBD infused beverages, with a company whose management can be summarized as follows:

“Phivida’s management team has a strong background from the beverage industry to branding, including former senior executives from Redbull, Proctor and Gamble and McKesson’s”

It gets better … because this is what they said about our Namaste:

“John – David Belfontaine, President and CEO of Phivida reports: “As Phivida continues to expand is CBD product offerings into a $1 Trillion global health and wellness markets, it is critical that we secure the strongest distribution partners. Ecommerce and digital marketing is a core horizontal within our greater strategic business plan, and Namaste is an ideal partner to expand our online presence into emerging markets around the world. We look forward to launching our global digital marketing and distribution platform with Namaste’s support as a key strategic partner.”

When a management team formerly from Redbull, P&G and McKesson’s think this highly of your company, you can only come to one conclusion..

Namazon

Marijuana Company of America $MCOA and Global #Hemp Group $GHG.ca Issue Final Report on New Brunswick Hemp / #CBD Project $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:38 AM on Wednesday, January 10th, 2018

15233 mcoa

  • Provides a final report on the first phase of their industrial hemp project in New Brunswick
  • In this first phase of MCOA’s and GHG’s multi-phase hemp project, the Partners successfully cultivated industrial hemp during the 2017 growing season
  • Objective of phase one was to re-introduce hemp into the area, to ensure that it could be productive under New Brunswick growing conditions, prior to significantly increasing cultivation acreage, and building a hemp processing facility in the region

Escondido, California–(January 10, 2018) – MARIJUANA COMPANY OF AMERICA INC. (OTC Pink: MCOA) (“MCOA” or the “Company“), an innovative hemp and cannabis corporation, and Global Hemp Group, Inc. (“GHG”) (CSE: GHG) (FSE: GHG) (OTC Pink: GBHPF) are pleased to provide a final report on the first phase of their industrial hemp project in New Brunswick.

On September 5, 2017, MCOA and GHG announced their joint venture to develop commercial hemp production on the Acadian peninsula of New Brunswick, Canada.

In this first phase of MCOA’s and GHG’s (the “Partners”) multi-phase hemp project, the Partners successfully cultivated industrial hemp during the 2017 growing season (see Phase One Hemp Trial Results below). For this phase of the project, the Partners only grew hemp for research purposes, as this was the first time in 20 years that industrial hemp was grown in the region. The objective of phase one was to re-introduce hemp into the area, to ensure that it could be productive under New Brunswick growing conditions, prior to significantly increasing cultivation acreage, and building a hemp processing facility in the region.

The Partners are preparing for proposed changes to Canadian legislation expected in 2018, that will permit cannabidiol (CBD) extraction from industrial hemp. Health Canada is currently consulting industry representatives regarding regulations that will accompany the new cannabis legislation expected by July 1, 2018.

The Partners are now focusing on the next season of crops. Farmers have been recruited and a minimum of 125 acres of hemp cultivation is planned for 2018, with the goal of increasing the acreage under cultivation to 1,000 acres by year three of the project. This first commercial crop will focus on CBD extraction. The Partners are currently considering sites in northeast New Brunswick to locate their processing facilities. In addition, discussions are underway regarding the purchase of extraction equipment for cannabinoids, and straw processing equipment for building materials. The companies expect the facilities to be in place and operational for the 2018 harvest in October.

Under the joint venture MCOA will facilitate access to international markets for the project’s CBD production, product development and distribution, while GHG will provide technical and management expertise. MCOA has Right of First Refusal as the primary off-taker of the cannabinoids from all future hemp cultivation projects.

RENEWAL OF GHG’S HEMP LICENSE IN CANADA

GHG’s industrial hemp license was renewed for 2018. Under current legislation, hemp flowers and leaves grown under field conditions cannot be processed. It is expected that this will be allowed under new 2018 regulations, but will still require additional licenses: one to extract the CBD and another to sell CBD for medical or non-medical purposes. In anticipation of this change, GHG will be applying for a license under the Narcotics Control Regulations (NCR) to extract CBD, and an additional license under the Access to Cannabis for Medical Purposes (ACMPR) to sell it to wholesale and retail customers in Canada.

FINAL TRIAL RESULTS

The trial consisted of fifteen test plots with three different varieties and as many planting densities of hemp, in two different locations east and west of Bathurst.

The trials were sampled, and collected materials were measured at Collège Communautaire du Nouveau Brunswick (CCNB), Grand Falls laboratory, where standard drying and measuring procedures were applied to the hemp straw, flowers, and leaves. Straw yields averaged 1.0-2.5 T/ha, whereas the combined flowers and leaves of the plant averaged 1.25-2.10 T/ha. The Partners are confident that with an earlier planting date, adequate soil preparation, and a higher fertilizer application, yields will be improved in future seasons.

Cannabinoid analysis of the flowers and leaves was completed by RPC – Science & Engineering (RPC), an accredited laboratory located in Fredericton, NB. Contrary to expectations leaves, rather than the flowers, contained a greater concentration of CBD, largely explained by laboratory procedures. The highest concentration that was found was the CFX-1 leaf sample that resulted in 1.46% for the 30 kg/ha plant density compared to 1.17% for the flowers. Also, it should be noted that the CBD concentration in flowers is consistently higher at densities of 30 kg/ha across all varieties that were tested.

Frank Giese, an advisor to GHG, will consult on the 2018 cultivation to assist in increasing both plant yield and cannabinoid production. Through his experience, he has bridged the fundamentals of scientific research and hemp/cannabis breeding, as well as the use and development of modern cultivation and processing techniques in his breeding work. He has become proficient in breeding cannabinoid rich varieties of hemp, as well as being very experienced in auto flower breeding.

Donald Steinberg, CEO of MCOA, stated, “We are excited to complete the first phase of industrial hemp trials in Canada, and we look forward to continue expanding operations in Canada. Our joint venture with GHG allows MCOA the opportunity to expand the Company’s operations on an international level. Both Companies are excited about the endless possibilities for hemp derived CBD product this year in Canada.”

About Marijuana Company of America, Inc.

MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

About Global Hemp Group Inc.

Global Hemp Group (“GHG”) is a publicly traded company founded in 2012, headquartered in British Columbia, Canada with base operations in Montreal and Southern California. The Company is focused on the production and processing of hemp and cannabis, and collaboration with companies that will enable GHG to develop and implement the Hemp Agro-Industrial Zone concept. Through partnerships, joint ventures and acquisitions, the Company will capture cash flow, revenues, and value, and establish a greater collective valuation.

Forward Looking Statements

This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
NetworkNewsWires/MCOA

Marijuana Company of America, Inc.
Investor Relations
1+(888)-777-4362
IR@mcoa.club

Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office

Tetra Bio-Pharma $TBP.ca Enters into Agreement to Acquire Remaining 20% Interest in Phytopain Pharma Subsidiary $AERO $CBDS $CGRW $APH.ca $GBLX #CBD #Marijuana

Posted by AGORACOM-JC at 9:13 AM on Tuesday, January 2nd, 2018

Logo tetrabiopharma rgb web

  • Announced that it has entered into a share purchase agreement  with entities controlled by André Rancourt, Chairman of the Board of Directors of the Corporation, and Guy Chamberland, Chief Scientific Officer of the Corporation
  • Under the terms of the Purchase Agreement, Tetra will acquire from the Vendors all of the remaining issued and outstanding common shares of Tetra’s subsidiary, Phytopain Pharma Inc.

OTTAWA, ONTARIO–(Jan. 2, 2018) Tetra – Bio-Pharma Inc. (“Tetra” or the “Corporation“) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development, today announced that it has entered into a share purchase agreement (the “Purchase Agreement“) with entities controlled by André Rancourt, Chairman of the Board of Directors of the Corporation, and Guy Chamberland, Chief Scientific Officer of the Corporation (collectively, the “Vendors“).

Under the terms of the Purchase Agreement, Tetra will acquire from the Vendors all of the remaining issued and outstanding common shares of Tetra’s subsidiary, Phytopain Pharma Inc. (“PPP“), currently held by the Vendors (representing 20% of the issued and outstanding shares of PPP) for an aggregate purchase price (the “Purchase Price“) of $12,425,089 (the “Transaction“). Upon completion of the Transaction, PPP will become a wholly-owned subsidiary of Tetra.

“Upon completion, this transaction will be a significant milestone for Tetra Bio-Pharma and all our stakeholders,” said Bernard Fortier, Tetra’s CEO.

“The two selling shareholders – our Chairman and our Chief Scientific Officer – are both committed to the long-term success of Tetra as evidenced by their agreement to accept shares in Tetra in lieu of an all- cash transaction. As well, a percentage of those shares are going to be released once certain key milestones for the company have been reached,” he said.

“This transaction will allow Tetra to gain 100% control of Phytopain Pharma, a key asset in the development of our pipeline of cannabinoid-based drugs and gives our company full flexibility to enter into other partnerships or agreements in the future.”

The Transaction is subject to customary closing conditions including, but not limited to, approval of the TSX Venture Exchange (“TSXV“) and any other approval that may be required by the TSXV.

The Transaction

Under the terms of the Purchase Agreement, the Purchase Price for the Transaction is comprised of the following:

  • Cash: An aggregate cash payment of $248,000 (the “Cash Payment“). Under the terms of the Purchase Agreement, the Cash Payment is payable in escrow as of the signature of the Purchase Agreement and has been paid to the Vendors’ legal counsel in trust for the Vendors pending receipt of approval for the Transaction from the TSXV. In addition, Tetra has agreed to pay the Vendors, immediately upon signature of the Purchase Agreement, a non-refundable amount of $200,000, payable out of the funds available for the Cash Payment, to induce the Vendors to provide an exclusivity of negotiation to the Purchaser for the Transaction.
  • Promissory Notes: Promissory notes issued by Tetra to the Vendors in an aggregate principal amount of $2,236,696 (the “Notes“), which Notes are payable in accordance with a specified milestone schedule as described in the Purchase Agreement. Pursuant to the terms of the Purchase Agreement, the Notes have been delivered to the Vendors’ legal counsel in trust for the Vendors pending receipt of approval for the Transaction from the TSXV.
  • Tetra Shares: Common shares of Tetra (“Common Shares“) will be issued to the Vendors as follows:
    • Upon completion of the Transaction, an aggregate of 2,485,218 Common Shares will be issued to the Vendors.
    • Upon completion of the Transaction, 7,455,653 Common Shares will be issued to
      Computershare Trust Company of Canada, as escrow agent (the “Escrow Agent“), to be held in escrow and released by the Escrow Agent under the terms and conditions set forth in the Purchase Agreement and the terms and conditions of an escrow agreement to be executed at closing by the Vendors, the Corporation and the Escrow Agent.

The Vendors under the Purchase Agreement are entities controlled by André Rancourt, Chairman of the Board of Directors of the Corporation, and Guy Chamberland, Chief Scientific Officer of the Corporation and are therefore considered “non-arm’s length parties” under the rules of the TSXV. Mr. Rancourt and Mr. Chamberland have properly disclosed their respective interest in the Transaction to the board of directors of the Corporation.

The Transaction constitutes a “related party transaction” within the meaning of Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions (“MI 61-101”). While MI 61-101 would generally subject the transaction to minority shareholder approval and formal valuation requirements, the Corporation will avail itself of the exemptions applicable under Section 5.5(a) of MI 61- 101.

Mr. Rancourt currently has ownership or direction and control over (i) an aggregate of 465,000 Common Shares, (ii) 1,600,000 options to acquire Common Shares and (iii) 4,000,000 Common Share purchase warrants, representing approximately 0.37% of the issued and outstanding Common Shares on a non- diluted basis and approximately 4.66% of the issued and outstanding Common Shares on a partially diluted basis. Further to the completion of the Transaction, and assuming that all of the Common Shares issued in escrow and allotted to Mr. Rancourt are released to Mr. Rancourt or an affiliate of Mr. Rancourt in accordance with the Purchase Agreement, Mr. Rancourt would then have ownership or direction and control over (i) 5,435,436 Common Shares, (ii) 1,600,000 options to acquire Common Shares and (iii) 4,000,000 Common Share purchase warrants, representing approximately 4.20% of the issued and outstanding Common Shares on a non-diluted basis and approximately 8.17% of the issued and outstanding Common Shares.

Mr. Chamberland currently has ownership or direction and control over (i) an aggregate of 1,250,000 Common Shares, (ii) 350,000 options to acquire Common Shares and (iii) 4,000,000 Common Share purchase warrants, representing approximately 1.00% of the issued and outstanding Common Shares on a non-diluted basis and approximately 4.32% of the issued and outstanding Common Shares on a partially diluted basis. Further to the completion of the Transaction, and assuming that all of the Common Shares issued in escrow and allotted to Mr. Chamberland are released to Mr. Chamberland or an affiliate of Mr. Chamberland in accordance with the Purchase Agreement, Mr. Chamberland would then have ownership or direction and control over (i) 6,220,436 Common Shares, (ii) 1,600,000 options to acquire Common Shares and (iii) 4,000,000 Common Share purchase warrants, representing approximately 4.78% of the issued and outstanding Common Shares on a non-diluted basis and approximately 8.70% of the issued and outstanding Common Shares.

Each of Mr. Rancourt and Mr. Chamberland proposes to acquire the common shares for investment purposes, and has no current intention to increase his beneficial ownership of, or control or direction over, securities of Tetra. These investments will be reviewed on a continuing basis and their holdings may be increased or decreased in the future.

The Transaction is subject to customary conditions including, but not limited to, approval of the TSXV. The Transaction has been unanimously approved by Tetra’s board of directors (with André Rancourt abstaining from voting) and Tetra anticipates that the Transaction will be completed in the first quarter of 2018.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid- based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products. More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Corporation believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Corporation’s ability to control or predict, that may cause the actual results of the Corporation to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Corporation, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Corporation’s business plan; the success of the Rx Princepsproduct offering and inhalation device; guidance on expected sales volumes associated with the Rx Princepsproduct offering and inhalation device; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Corporation’s public disclosure record on file with the relevant securities regulatory authorities. Although the Corporation has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Bernard Fortier, MBA
Chief Executive Officer
(514) 360-8040 Ext. 206
bernard.fortier@tetrabiopharma.com
www.tetrabiopharma.com

Aurora $ACB.ca and Namaste $N.ca $NXTTF to Complete Strategic Private-Label Software and Patient Referral Agreements $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 7:19 AM on Tuesday, January 2nd, 2018

Nlogo

  • Namaste will provide CanvasRx with a customized, CanvasRx-branded version of NamasteMD
  • Namaste will provide CanvasRx with a two-year exclusivity period for the private label version of NamsteMD.com in Canada

EDMONTON and VANCOUVER, Jan. 2, 2018 – Aurora Cannabis Inc. (the “Company” or “Aurora”) (TSX: ACB) (OTCQX: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) and Namaste Technologies Inc. (“Namaste”) (CSE: N) (FRANKFURT: M5BQ) (OTCMKTS: NXTTF) today announced the signing of a binding term sheet towards a final Private-Label Software Agreement (“Private Label Agreement”), whereby Namaste will provide Aurora’s wholly-owned subsidiary, CanvasRx Inc. (“CanvasRx”) with a customized version of Namaste’s patient acquisition tool, NamasteMD.com (“NamasteMD”),  as well as desktop and mobile applications for Google Android and Apple iOS platforms. The companies have 30 days to complete a final agreement.

Private Label Agreement

NamasteMD is an online telemedicine platform for patient consultation and registration, bringing together Namaste`s tested technology platform, including certain proprietary authentication technologies, as well as consultation, education and medical document issuance processes. Under the terms of the Private Label Agreement:

  • Namaste will provide CanvasRx with a customized, CanvasRx-branded version of NamasteMD
  • Namaste will provide CanvasRx with a two-year exclusivity period for the private label version of NamsteMD.com in Canada
  • Namaste will initially provide the application for both the Google Android and Apple iOS platforms
  • CanvasRx will require their own doctors and/or nurse practitioners to operate the platform
  • Commercial terms of the agreement are not disclosed
  • In consideration of Aurora’s assistance for the future optimization of NamasteMD, Namaste has issued Aurora 500,000 stock options, exercisable at $3.35 per common share for 48 months, vesting quarterly over 12 months.

Support Services Agreement

In addition, the companies have also signed a non-binding, non-exclusive Letter of Intent to complete a final Consultation & Support Services Agreement (“Consultation Agreement”), whereby Namaste will provide patient referral services to Aurora, where applicable under Canada’s Access to Cannabis for Medical Purposes (“ACMPR”) regulations. Under the terms of the Consultation Agreement:

  • Namaste shall provide certain patient-focused education and strain selection services, as well as assistance in preparing the requisite paperwork (Medical Documentation) for registering patients with Aurora
  • The Agreement is non-exclusive for a one-year term
  • Namaste shall provide the services under the agreement on preferential terms to Aurora
  • Commercial terms of the Consultation Agreement are not disclosed

The agreements further strengthen the strategic ties between the two companies, who already collaborate on eCommerce (sale of Namaste-sourced, curated selection of vaporizers through Aurora website, utilizing Namaste’s technology platform), and the distribution of BC Northern Lights products. Once completed, the new agreements will provide Namaste with recurring revenues through the private label platform, while Aurora will be the only licensed producer able to offer Namaste`s streamlined online patient acquisition platform under its own (CanvasRx) brand.

Management Commentary

“NamasteMD provides an innovative and efficient extension to our industry-leading in-person cannabis counseling and education services provided through CanvasRx,” said Terry Booth, CEO. “The new platform will enable us to extend our industry leading patient care to areas where we currently have no physical presence. This will allow us to leverage the strength of both the CanvasRx and Aurora brands, without having to commit to substantial investments in brick and mortar facilities. Namaste is a trusted partner with whom we already successfully collaborate on two promising initiatives, and we look forward to extending our partnership based on innovation and customer care excellence.”

Sean Dollinger, President and CEO of Namaste added, “We are thrilled to have Aurora, the industry’s most innovative and dynamic Licensed Producer, as our preferred strategic partner. Our drive to innovate meets the cannabis industry`s need for reliable technological solutions to improve operational efficiencies and expand the customer experience. We are very proud to be aligned with Aurora’s team, and look forward to executing on our ongoing collaboration.”

About Aurora

Aurora’s wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada’s Access to Cannabis for Medical Purposes Regulations (“ACMPR”). The Company operates a 55,200 square foot, state-of-the-art production facility in Mountain View County, Alberta, known as “Aurora Mountain”, a second 40,000 square foot high-technology production facility known as “Aurora Vie” in Pointe-Claire, Quebec on Montreal’s West Island, and is currently constructing an 800,000 square foot production facility, known as “Aurora Sky”, at the Edmonton International Airport, as well as is completing a fourth facility in Lachute, Quebec through its wholly owned subsidiary Aurora Larssen Projects Ltd.

In addition, the Company holds approximately 17.23% of the issued shares in leading extraction technology company Radient Technologies Inc., based in Edmonton, and is in the process of completing an investment in Edmonton-based Hempco Food and Fiber for an ownership stake of up to 50.1%. Furthermore, Aurora is the cornerstone investor with a 22.9% stake in Cann Group Limited, the first Australian company licensed to conduct research on and cultivate medical cannabis. Aurora also owns Pedanios, a leading wholesale importer, exporter, and distributor of medical cannabis in the European Union, based in Germany. The Company offers further differentiation through its acquisition of BC Northern Lights Ltd. and Urban Cultivator Inc., industry leaders, respectively, in the production and sale of proprietary systems for the safe, efficient and high-yield indoor cultivation of cannabis, and in state-of-the-art indoor gardening appliances for the cultivation of organic microgreens, vegetables and herbs in home and professional kitchens. Aurora’s common shares trade on the TSX under the symbol “ACB”.

About Namaste Technologies Inc.

Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through e-commerce sites in 26 countries and with 5 distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, US, Canada and Germany, and has opened new supply channels into emerging markets, including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis distribution license (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

On behalf of the Boards of Directors

Terry Booth

Sean Dollinger

Chief Executive Officer

Chief Executive Officer

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Aurora and Namaste are under no obligation, and expressly disclaim any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither TSX or CSE, nor their Regulation Services Provider (as that term is defined in the policies of Toronto Stock Exchange and CSE) accept responsibility for the adequacy or accuracy of this release.

Namaste $N.ca Announces Wholesale Supply LOI With Israel-Based BRLEV $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 9:42 AM on Wednesday, December 27th, 2017

Nlogo

  • Signed a Letter of Intent (“LOI”) with BRLEV AGRICULTURAL CROPS LTD
  • BRLEV will supply CannMart with high quality medical cannabis, to be imported by CannMart from Israel and offered in the Company’s online marketplace

VANCOUVER, British Columbia, Dec. 27, 2017 — Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N)(FRANKFURT:M5BQ)(OTCMKTS:NXTTF) is pleased to announce that it has signed a Letter of Intent (“LOI”) with BRLEV AGRICULTURAL CROPS LTD. (“BRLEV”), through its wholly owned subsidiary, Cannmart Inc. (“CannMart”), whereby BRLEV will supply CannMart with high quality medical cannabis, to be imported by CannMart from Israel and offered in the Company’s online marketplace. BRLEV is Israel’s largest licensed producer of medical cannabis, with over 40 years of experience in commercial agricultural production and export. BRLEV will work with Namaste to export medical cannabis to the Canadian market, which will fall under Canada’s Access to Cannabis for Medical Purposes Regulations (“ACMPR”) guidelines. The LOI and the proposed medical cannabis supply agreement (“Supply Agreement”) highlight Namaste’s intentions of becoming Canada’s leading online retailer for medical cannabis products, by focusing on importation of high quality medical cannabis from industry-leading countries like Israel. Namaste believes that the demand for imported cannabis and the opportunity it presents has been largely overlooked. This deal solidifies Namaste’s commitment in seeking the best cannabis products in global markets and offering them to Canadian cannabis users.

Terms of the LOI:

  • Namaste will submit purchase orders to BRLEV for medical cannabis.
  • Namaste will provide 50% payment against each purchase order once the goods arrive at the airport and have been tested by a third-party laboratory facility. The balance of payment will be due within 30 days from the shipment date.
  • Product cost to Namaste will be determined as 30% of Namaste’s retail price.
  • Namaste will be responsible for shipping and import costs.
  • Namaste’s product branding and naming conventions for each strain will adhere to Israeli government requirements where applicable.
  • Namaste will mark each customer package with BRLEV’s name and logo.

The LOI and proposed Supply Agreement reinforce Namaste’s effort to provide imported medical cannabis products to its patients by offering the largest variety of products from domestic and international producers. BRLEV boasts one of the largest production facilities in Israel and is a strong partner for Namaste. Namaste believes that BRLEV’s existing license and infrastructure will be suited to accommodate the Company’s expected demand for high quality Israeli grown medical cannabis. Namaste is highly focused on cannabis importation for its CannMart facility and specifically on sourcing from the Israeli market. This partnership will allow Namaste to offer greater value for its patients by allowing CannMart to provide a larger offering in comparison with domestic ACMPR licensed producers.  The Company expects to see strong demand for imported cannabis products and looks forward to a growing relationship with BRLEV and its management team.

Management Commentary
Asaf Bardichev, President and CEO of BRLEV comments: “BRLEV is very excited to announce the signing of this LOI. We see Namaste as a central and leading figure in the growing Canadian retail market and see this as a great opportunity for collaboration. We believe that the partnership with Namaste that we are beginning now can be a long and lasting one. It will be one that strengthens Namaste, BRLEV, and the Canadian medical cannabis market.”

Sean Dollinger, President and CEO of Namaste comments: “While the Canadian market continues to be a leader with regards to the production of high quality cannabis, Namaste remains of the opinion that Canadian consumers will demand other high-quality products from markets abroad. Through our partnership with BRLEV, Namaste fully intends to meet that demand. This transaction represents the first of many partnerships by which Namaste intends to create the largest and most diverse marketplace for Canadian cannabis consumers. We are very pleased to have signed this LOI and are looking forward to working with the BRLEV Group. Namaste believes this represents a strong partnership based on BRLEV’s credentials and experience in cultivation and agricultural export. The BRLEV management team has exceptional talents for cultivation and production of the highest quality medical cannabis in the Israeli market. We look forward to working with BRLEV and their team in creating the most diverse offering of medical cannabis in the Canadian online retail marketplace.”

About BRLEV
The BRLEV Group manages cannabis based medicine production from mother plants to final product. The group is fully licensed in all aspects of cannabis cultivation and processing as well as in the manufacturing of cannabis based medication in Israel. With an impressive lineup of high-end facilities and over 40 years of experience in agriculture the BRLEV group meets the highest industry standards including GMP, Global Gap and Tesco. Working closely with the leading Israeli research bodies in plant genetics, virus and pest control, cannabis processing and active substance extraction, BRLEV uses state of the art methods and knowledge in cannabis cultivation and processing. The BRLEV group has also secured a cannabis trading license which enables the group to start exporting its products overseas as soon as export regulations are in place.

About Namaste Technologies Inc.
Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through e-commerce sites in 26 countries and with 5 distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, US, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis distribution license (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

On behalf of the Board of Directors

“Sean Dollinger”
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: info@namastetechnologies.com

Further information on the Company and its products can be accessed through the links below:

www.namastetechnologies.com
www.namastevaporizers.co.uk
www.everyonedoesit.co.uk

FORWARD LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

FEATURE: Tetra Bio-Pharma $TBP.ca – Only Pharma Company To Have Clinical Studies for Smoked #Marijuana #MMJ #CBD

Posted by AGORACOM-JC at 11:38 AM on Tuesday, October 24th, 2017

WHY TETRA BIO-PHARMA?

 

  • Only pharmaceutical company to have clinical studies for smoked marijuana;
  • Signed a letter of intent with a major player of the healthcare specialty industry
  • Will benefit from the intellectual property created within the cannabis health research Chair from the University of New Brunswick
  • Company is financially sound, with enough cash to pay for the $1.2 million Phase III clinical trials of PPP001.
  • Filing a clinical trial application in the coming weeks to therapeutic products directorate to initiate its Phase 3 clinical trial of PPP001 in terminal cancer patient
  • Focused on expanding commercialization partnerships internationally for product pipeline – Interest has been shown from the USA, Germany, Ireland, Brazil and Mexico;
  • Initial demand forecasted in New Brunswick for PPP001 using the ACMPR license is more than expected

Global Hemp Group $CHG.ca and Marijuana Company of America $MCOA to Enter Joint Venture Agreement with Space Cowboys’ Colorado Farm

Posted by AGORACOM-JC at 11:18 AM on Tuesday, October 10th, 2017

15233 mcoa

  • Marijuana Company of America Inc.  and Global Hemp Group  announce that they have jointly entered into a letter of intent with Space Cowboys, Inc. or the purposes of forming a joint venture
  • Space Cowboys is an existing fully licensed and compliant hemp-derived cannabinoid producer in Colorado

Escondido, California–(October 10, 2017) – Marijuana Company of America Inc. (OTC Pink: MCOA) (“MCOA” or the “Company“), an innovative hemp and cannabis corporation, and Global Hemp Group (CSE: GHG) (FSE: GHG) (OTC Pink: GBHPF), (collectively the “Companies“), are pleased to announce that they have jointly entered into a letter of intent with Space Cowboys, Inc. (“Space Cowboys“) for the purposes of forming a joint venture (the “Joint Venture“). Space Cowboys is an existing fully licensed and compliant hemp-derived cannabinoid producer in Colorado.

Pursuant to the terms of the letter of intent and subject to the Companies obtaining sufficient financing, the Companies will invest US$2.5 Million in exchange for a 25% equity interest in Space Cowboys. The investment funds will be used to expand Space Cowboys’ cultivation operation.

Space Cowboys is in its fourth year of operation and is in full compliance with Colorado state law and the Colorado Department of Agriculture. The business consists of both indoor and outdoor cultivation of highly concentrated CBD hemp on properties located in Longmont and Loveland, Colorado. Space Cowboys’ current hemp crops will be harvested in the latter part of October and prepared for extraction of the high-value cannabinoids.

In addition to the potential revenue streams generated from Space Cowboys’ ongoing high cannabinoid hemp production, this Joint Venture will provide the opportunity to be a part of a legal operation with the extensive knowledge and experience required to cultivate and process industrial hemp into raw cannabinoids. For MCOA, it will also provide a consistent cannabinoid supply from a known source and trusted partner for its hempSMART™ product line. This will also enable Global Hemp Group to develop its Hemp Agro-Industrial Zone concept.

“MCOA has always been interested in developing hemp farms and processing here in the United States. By initiating this Joint Venture, the Company will accomplish this objective along with securing its supply chain of raw cannabinoids. It is an important step in the continued development of the hempSMART brand, which distributes a hemp-based Cannabinoid product line,” said CEO, Donald Steinberg.

The transaction is subject to a number of conditions, including but not limited to, completion of satisfactory due diligence, entry into a definitive agreement and receipt of any necessary regulatory approvals. There is no assurance such conditions will be met or that the Companies will be able to secure the financing necessary to complete the transaction on acceptable terms or at all.

About Space Cowboys

Space Cowboys operates hemp farms in the state of Colorado for the primary purpose of Cannabinoid production. Space Cowboys’ operations are in full compliance with Colorado state law and the Colorado Department of Agriculture.

About Global Hemp Group Inc.

Global Hemp Group (“GHG”) is a publicly traded company founded in 2012, headquartered in British Columbia, Canada with base operations in Montreal and Southern California. The Company is focused on the production and processing of hemp and cannabis, and collaboration with companies that will enable GHG to develop and implement the Hemp Agro-Industrial Zone concept. Through partnerships, joint ventures and acquisitions, the Company will capture cash flow, revenues, and establish a greater collective valuation.

About Marijuana Company of America, Inc.

MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products containing CBD under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

Forward Looking Statements

This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Email Contact

Marijuana Company of America $MCOA.us Announces #hempSMART 2.0 With New Website and Affiliate Program

Posted by AGORACOM-JC at 8:54 AM on Thursday, September 7th, 2017

15233 mcoa

  • Announced a major update of hempSMART™, the Company’s wellness focused Cannabidiol (CBD) marketing and distribution division
  • www.hempSmart.com and its network marketing platform have been completely redeveloped
  • Provides a more user friendly experience to its affiliates and customers

ESCONDIDO, CA–(Sep 7, 2017) – MARIJUANA COMPANY OF AMERICA (“MCOA” or the “Company“) (OTC PINK: MCOA), an innovative cannabis and hemp marketing and distribution company, is pleased to announce a major update of hempSMART™, the Company’s wellness focused Cannabidiol (CBD) marketing and distribution division.

The hempSMART website: www.hempSmart.com and its network marketing platform have been completely redeveloped to provide a more user friendly experience to its affiliates and customers, and to also provide users with the comprehensive tools necessary to succeed in the growing $1.9 Trillion Wellness Industry.

The new website and network marketing platform have a significantly improved design, expanded content and a more user friendly e-commerce platform that offers the ability to easily expand due to the flexibility of the business platform it is built on. Affiliate’s will now experience a more effective, reliable and streamlined sales process to rapidly expand the Company’s consumer base and Affiliate success stories.

The new hempSMART Affiliate sales and distribution method is designed to ensure that our Affiliates play a leading role in the rapidly emerging Cannabidiol (CBD) movement within the Wellness Industry. The Company is in ongoing discussions about expanding internationally into multiple countries in 2018.

“The solid foundation that our new system and online platform offers will enable our Affiliates to fully utilize their abilities to grow their organizations in the U.S. and globally. Our team is in place, our products are being well received in the market, and we are in an industry that is experiencing exponential growth. We are building a strong foundation of technology, products and a strategic marketing plan that is designed to offer great benefits to our Affiliates who are the key to our success. We look forward to a robust and exciting time for our company,” said CEO, Donald Steinberg.

About Marijuana Company of America, Inc.

MCOA is a corporation engaged in business including, but not limited to: (1) product research and development of legal hemp-based consumer products containing CBD under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

FORWARD LOOKING STATEMENT
This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:
MarijuanaCompanyofAmerica.com
hempSMART.com
agoracom.com/ir/MarijuanaCompanyofAmerica

Marijuana Company of America, Inc.
Investor Relations
1+(888)-777-4362
IR@mcoa.club

$MCOA.us At The Forefront of #Hemp Marketing and Distribution, Recently Announced $5 Million Fixed Funding Commitment

Posted by AGORACOM-JC at 9:25 AM on Tuesday, August 8th, 2017

15233_mcoa

MCOA: OTC

RECENT EVENTS

  • Announced a $5 Million Fixed Funding Commitment READ MORE
  • Company Announces the Filing of Form 10 Registration Statement with SEC READ MORE
  • Launch of New Website READ MORE
  • Company Invests in Global Payout’s MoneyTrac READ MORE
  • Announced Formation of Strategic Advisory Board READ MORE
  • Finalized Joint Venture Agreement With Bougainville Ventures in Washington State READ MORE
  • Completed PCOAB Audit READ MORE

BRANDS

MCOA is aggressively building a portfolio of investments and joint ventures that represent the highest integrity and professionalism in the legal cannabis markets.